Global Gabapentin Market Share, Size, Trends, Industry Analysis Report, By Dosage (Tablet, Capsule, Oral Solutions), By Type (Generic Branded), By Application, By Distribution Channel; By Region; Segment Forecast, 2023 - 2032
- Published Date:May-2023
- Pages: 119
- Format: PDF
- Report ID: PM3214
- Base Year: 2022
- Historical Data: 2019-2021
Report Outlook
The global gabapentin market was valued at USD 1,981.60 million in 2022 and is expected to grow at a CAGR of 4.37% during the forecast period. Gabapentin is a medication that is primarily used to treat seizures and nerve pain. It is also used to treat other conditions such as anxiety, restless leg syndrome, and hot flashes. Gabapentin belongs to a class of medications called anticonvulsants, which work by decreasing abnormal activity in the brain.
Know more about this report: Request for sample pages
Gabapentin is available in various forms, including capsules, tablets, and oral solution. It is typically taken orally, with or without food, as directed by a healthcare provider. The dosage and frequency of use may vary depending on the condition being treated and the patient's response to the medication.
The active ingredient in gabapentin is gabapentin, which is a structural analog of the neurotransmitter gamma-aminobutyric acid (GABA). While gabapentin does not bind to GABA receptors, it does increase the synthesis and release of GABA in the brain. This results in a decrease in the activity of certain neurons that can cause seizures or pain.
Gabapentin is generally well-tolerated, but like any medication, it can cause side effects. Common side effects of gabapentin include dizziness, drowsiness, headache, and nausea. More serious side effects may include difficulty breathing, hives, and swelling of the face, lips, tongue, or throat. Patients who experience any of these symptoms should seek immediate medical attention.
Gabapentin should not be used by patients with a history of hypersensitivity to gabapentin or any of its components. It should also be used with caution in patients with a history of kidney disease, as gabapentin is primarily excreted through the kidneys.
In conclusion, gabapentin is a medication that is primarily used to treat seizures and nerve pain. It works by decreasing abnormal activity in the brain, which can help to control seizures and alleviate pain. While gabapentin is generally well-tolerated, it can cause side effects and should be used with caution in certain patient populations. As with any medication, patients should discuss the potential benefits and risks of gabapentin with their healthcare provider before starting treatment.
Know more about this report: Request for sample pages
Industry Dynamics
Growth Drivers
Gabapentin is a medication that is primarily used to treat seizures, neuropathic pain, and restless leg syndrome. It is also sometimes used to treat anxiety, insomnia, and certain types of bipolar disorder. Gabapentin is an anticonvulsant drug that works by affecting the chemicals and nerves in the body that are involved in seizures and pain.
There are several growth drivers that are expected to propel the demand for gabapentin in the coming years. One of the key drivers is the increasing incidence of neuropathic pain and seizures. With the aging population, the prevalence of chronic pain and neurological disorders is expected to rise, leading to an increased demand for medications like gabapentin.
Another driver of growth for gabapentin market is the increasing use of the drug for off-label indications such as anxiety, insomnia, and bipolar disorder. While the drug has not been specifically approved by the FDA for these uses, there is a growing body of evidence to support their effectiveness in treating these conditions.
Additionally, the rise of e-commerce has made it easier for consumers to purchase medications like gabapentin online, increasing access to the drug for patients who may not have easy access to a physical pharmacy.
Report Segmentation
The market is primarily segmented based on Dosage, Type, Application, Distribution Channel and Region.
|
By Dosage |
By Type |
By Application |
By Distribution Channel |
By Region |
|
|
|
|
|
Know more about this report: Request for sample pages
The Capsule segment is expected to witness the fastest growth in 2022
The pharmaceutical industry is a vast and rapidly growing sector that plays a crucial role in improving public health around the world. Among the various types of dosage forms used in pharmaceuticals, capsules are gaining popularity and are expected to witness the fastest growth in the coming years. Capsules are a type of dosage form that are made of a shell enclosing medication in a solid or liquid form. The shell can be made of various materials, including gelatin, vegetarian alternatives, and other polymer-based materials.
The capsule segment is expected to grow rapidly due to several factors. One of the primary drivers of growth is the increasing demand for easy-to-swallow dosage forms. Capsules are often easier to swallow than tablets, particularly for patients with swallowing difficulties, children, and the elderly. Additionally, capsules can be formulated to provide targeted drug delivery, which can improve efficacy and minimize side effects.
Another driver of growth in the capsule segment is the increasing demand for specialized formulations. Capsules can be formulated in a variety of ways, such as extended-release, delayed-release, and targeted-release formulations. These specialized formulations allow for better control over the delivery of the drug, which can improve efficacy and minimize side effects.
The Hospital Pharmacy segment is expected to witness largest market share in 2022
The hospital pharmacy segment is the healthcare industry, and it is expected to witness the largest market share among all pharmacy segments in the coming years. Hospital pharmacies are responsible for providing medications, medical supplies, and other healthcare products to patients within a hospital setting.
There are several factors driving the growth of the hospital pharmacy segment. One of the primary drivers is the increasing demand for high-quality healthcare services, particularly in emerging economies. As the demand for healthcare services continues to grow, hospitals are expanding their operations and investing in new technologies, including advanced pharmacy services.
Another driver of growth in the hospital pharmacy segment is the increasing prevalence of chronic diseases, such as cancer, diabetes, and heart disease. These diseases require ongoing treatment and management, which can involve complex medication regimens. Hospital pharmacies play a critical role in managing these medications and ensuring that patients receive the right medication at the right time.
Furthermore, the rise of personalized medicine is driving growth in the hospital pharmacy segment. Personalized medicine involves tailoring treatments to individual patients based on their unique genetic makeup, lifestyle, and other factors. Hospital pharmacies are well-positioned to provide personalized medicine services, as they have access to patient medical records and can work closely with physicians to develop personalized treatment plans.
North America and Europe are expected to remain the largest markets for hospital pharmacies, while Asia-Pacific is expected to be the fastest-growing region due to increasing demand for healthcare services and expanding hospital infrastructure.
The demand in North America is expected to witness significant growth during forecast period
Gabapentin is a medication primarily used to treat epilepsy and neuropathic pain. It is also used off-label to treat anxiety disorders, bipolar disorder, and other conditions. The demand for Gabapentin is expected to increase in various regions due to its efficacy and safety profile.
North America, Gabapentin is widely prescribed and is among the top 30 most prescribed medications in the United States. The demand for Gabapentin in North America is expected to continue to grow due to the increasing prevalence of chronic pain and neurological disorders.
In Europe, Gabapentin is also a commonly prescribed medication, particularly for the treatment of neuropathic pain. The demand for Gabapentin in Europe is expected to increase due to the aging population and the rising incidence of chronic pain.
The Asia-Pacific region is expected to witness significant growth in the demand for Gabapentin due to the increasing prevalence of neurological disorders, such as epilepsy and neuropathic pain. Additionally, the rising healthcare spending and increasing awareness about the benefits of Gabapentin are expected to drive the demand for the medication in the region.
Competitive Insight
Some of the major players of the gabapentin market are Pfizer Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Ltd., Lupin Limited, Mylan N.V., Cipla Limited, Hikma Pharmaceuticals PLC, Arbor Pharmaceuticals, Inc., Zydus Cadila Healthcare Limited, Glenmark Pharmaceuticals Ltd.
Recent Developments
- April 2021, Pfizer announced the launch of its oral JAK inhibitor, XELJANZ, for the treatment of ulcerative colitis in Japan.
- July 2021, Pfizer announced the launch of its biosimilar, RUXIENCE, for the treatment of rheumatoid arthritis.
- September 2021, Pfizer announced the acquisition of a privately held company, Amplyx Pharmaceuticals, focused on developing treatments for life-threatening infections.
Global Gabapentin Market Report Scope
|
Report Attributes |
Details |
|
Market size value in 2023 |
USD 2,066.22 Million |
|
Revenue forecast in 2032 |
USD 3,036.38 Million |
|
CAGR |
4.37% from 2023 - 2032 |
|
Base year |
2022 |
|
Historical data |
2019 - 2021 |
|
Forecast period |
2023 - 2032 |
|
Quantitative units |
Revenue in USD million and CAGR from 2023 to 2032 |
|
Segments covered |
By Product, By Region |
|
Regional scope |
North America, Europe, Asia Pacific, Latin America; Middle East & Africa |
|
Key companies |
Pfizer Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd. Aurobindo Pharma Ltd., Lupin Limited, Mylan N.V., Cipla Limited, Hikma Pharmaceuticals PLC, Arbor Pharmaceuticals, Inc., Zydus Cadila Healthcare Limited, Glenmark Pharmaceuticals Ltd., Apotex Inc., Torrent Pharmaceuticals Ltd., Alembic Pharmaceuticals Ltd., Wockhardt Ltd. |
FAQ's
The global gabapentin market size is expected to reach USD 3,036.38 million by 2032.
Key players in the gabapentin market are Pfizer Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Ltd., Lupin Limited, Mylan N.V., Cipla Limited, Hikma Pharmaceuticals PLC.
North America contribute notably towards the global gabapentin market.
The global gabapentin market expected to grow at a CAGR of 4.37% during the forecast period.
The gabapentin market report covering key segments are dosage, type, application, distribution channel and Region.
